Alnylam Pharmaceuticals (LTS:0HD2) Moat Score: 6/10 (As of Jul. 04, 2026)


LTS:0HD2 Alnylam Pharmaceuticals Inc LTS:0HD2
67 GF Score
Price $312.13
GF Value $517.19
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alnylam Pharmaceuticals Moat Score?

Alnylam Pharmaceuticals LTS:0HD2 67 Moat Score is 6 as of Jul. 04, 2026. GuruFocus rates LTS:0HD2 with a GF Score™ of 67/100 and a GF Value™ of $517.19 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,399 Biotechnology companies, Alnylam Pharmaceuticals ranks better than 98.93% on this metric.

Alnylam Pharmaceuticals has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Alnylam Pharmaceuticals has Narrow Moat: Alnylam has a strong narrow moat due to its valuable intellectual property and patents in RNAi therapeutics. It has a solid pipeline and consistent R&D capabilities, but lacks the scale and brand strength for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Alnylam Pharmaceuticals might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Alnylam Pharmaceuticals  (LTS:0HD2) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Alnylam Pharmaceuticals Moat Score Related Terms

LTS:0HD2 vs RVMD, ONC, MRNA: Moat Score Comparison

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alnylam Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Moat Score falls into.


LTS:0HD2
67GF Score
Alnylam Pharmaceuticals Inc LTS:0HD2
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Alnylam Pharmaceuticals (LTS:0HD2) has a Moat Score of 6 as of Jul. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #15 out of 1399 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Alnylam Pharmaceuticals' Moat Score too high?
Alnylam Pharmaceuticals' current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. Alnylam Pharmaceuticals' value of 6 is 200% above this industry median. Based on the distribution chart, Alnylam Pharmaceuticals ranks #15 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alnylam Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Moat Score compare to RVMD and ONC?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #15 out of 1399 companies for Moat Score. This places Alnylam Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Alnylam Pharmaceuticals' value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alnylam Pharmaceuticals's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $517.19, compared to a current price of $312.13 — trading 39.6% below its estimated fair value. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. Alnylam Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Moat Score is 6 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?

Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued. The current stock price of $312.13 is trading 39.6% below its estimated GF Value™ of $517.19. GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for LTS:0HD2:

  • Moat Score: 6
  • GF Value™: $517.19 vs. price of $312.13 (39.6% below fair value)
  • GF Score™: 67/100 with 3 warning signs
  • Industry Position: 200% above the Biotechnology median (#15 of 1399)

No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alnylam Pharmaceuticals Business Description

Address 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
67GF Score

Get the complete analysis for LTS:0HD2

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$312.13
Price
$517.19
GF Value